U.S. Electrical Stock News

NasdaqGS:SDGR
NasdaqGS:SDGRHealthcare Services

A Look At Schrödinger (SDGR) Valuation After Earnings Miss And Bunsen AI Co Scientist Launch Plans

Schrödinger (SDGR) is back in focus after first quarter 2026 results combined a reported earnings miss with 12% growth in Annual Contract Value, along with fresh attention on its upcoming Bunsen AI co-scientist launch. See our latest analysis for Schrödinger. Recent trading reflects this renewed interest, with a 1 month share price return of 16.59% and 7 day share price return of 11.04%. However, the year to date share price return of negative 26.14% and 1 year total shareholder return of...
NasdaqGM:ACMR
NasdaqGM:ACMRSemiconductor

ACM Research (ACMR) Margin Compression To 9.5% Tests Bullish Growth Narrative

ACM Research (ACMR) opened 2026 with Q1 revenue of US$231.3 million and basic EPS of US$0.26, alongside trailing twelve month revenue of US$960.2 million and EPS of US$1.40 that frame the latest quarterly print. Over the past six quarters, the company has seen quarterly revenue range from US$172.3 million to US$269.2 million and basic EPS move between US$0.12 and US$0.56, giving investors a clear view of how top line and per share earnings have tracked into the current TTM profile. With...
NasdaqGS:CGON
NasdaqGS:CGONBiotechs

CG Oncology (CGON) Deep LTM Losses Test Bullish Late Stage Pipeline Narratives

CG Oncology (CGON) has just closed out FY 2025 with Q4 revenue of US$2.3 million and a basic EPS loss of US$0.52, alongside a net income loss of US$41.3 million, as the company continues to invest heavily in its pipeline. Over the last twelve months, revenue has summed to US$4.0 million and basic EPS has come in at a loss of US$2.08. This gives investors a clear view of a business that is still in a development phase and running with intentionally thin margins while it pushes its late stage...
NYSE:NVST
NYSE:NVSTMedical Equipment

Is It Time To Reassess Envista Holdings (NVST) After Its Recent Share Price Pullback

If you are wondering whether Envista Holdings at US$24.29 offers good value or is already fully priced, the recent share performance gives you a useful starting point. The stock has pulled back 6.4% over the last 7 days and 4.0% over the last 30 days. It sits 12.0% higher year to date and 36.7% above where it was a year ago, while the 3 year and 5 year returns of 26.7% and 44.7% highlight a tougher longer term journey. Recent coverage has focused on Envista Holdings as a dental equipment and...
NYSE:LH
NYSE:LHHealthcare

Is It Too Late To Reconsider Labcorp Holdings (LH) After Recent Share Price Pullback

Wondering if Labcorp Holdings at around US$258 a share still offers value, or if most of the opportunity is already priced in? This article walks through the key signals you can use to judge that for yourself. The stock has been fairly steady over the last week with a 0.5% return, has a 4.1% decline over the past month, yet sits on a 4.8% return over 1 year and 41.6% over 3 years. This raises the question of whether the current price reflects the business fundamentals. Recent headlines...
NYSE:UI
NYSE:UICommunications

Ubiquiti (UI) Earnings Surge And 29.9% Margin Spark Debate On Valuation Premium

Ubiquiti (UI) has put up another big quarter, with Q2 2026 revenue of US$814.9 million and basic EPS of US$3.86, while trailing 12 month EPS sits at US$14.69 on revenue of about US$3.0 billion and earnings growth over that period is described as a 99.7% jump. The company has seen quarterly revenue move from US$599.9 million and EPS of US$2.26 in Q2 2025 to US$814.9 million and EPS of US$3.86 in Q2 2026, and trailing 12 month net profit margin is now stated at 29.9% versus 20.7% a year...
NasdaqGS:CLOV
NasdaqGS:CLOVHealthcare

Has Clover Health Investments (CLOV) Share Surge Left More Room Based On Cash Flow Value?

Wondering whether Clover Health Investments at US$2.82 is still a bargain or already pricing in its prospects? This breakdown will help you judge what you are really paying for. The stock has had a strong run over shorter periods, with returns of 2.5% over 7 days, 48.4% over 30 days and 17.0% year to date. However, the 1 year return sits at a 24.8% decline and the 3 year return is very large at 196.7% compared to a 61.2% decline over 5 years. Recent headlines have focused on the company as a...
NasdaqGS:LYFT
NasdaqGS:LYFTTransportation

Lyft (LYFT) Posts 45% Net Margin And Profitability Spike That Challenges Bearish Narratives

Lyft (LYFT) closed FY 2025 with fourth quarter revenue of US$1,592.7 million and basic EPS of US$6.88, setting a high bar for a year in which trailing 12 month EPS reached US$6.92 and revenue stood at US$6.3 billion alongside very large year over year earnings growth and a 45% net profit margin. Over the past six quarters, the company has seen quarterly revenue move from US$1,522.7 million in Q3 2024 to between US$1,450.2 million and US$1,685.2 million across FY 2025, while basic EPS ranged...
NasdaqGS:CRWV
NasdaqGS:CRWVIT

CoreWeave (CRWV) Q4 Loss Of US$452m Reinforces Profitability Concerns Despite Revenue Scale

CoreWeave (CRWV) has just wrapped up FY 2025 with Q4 total revenue of US$1.6b, a basic EPS loss of US$0.89 and net income loss of US$452.0m. This caps off a year in which trailing twelve month revenue reached US$5.1b alongside a TTM basic EPS loss of US$2.75. Over the past six reported quarters, the company has seen revenue move from US$584.0m in Q3 2024 to US$1.6b in Q4 2025. During the same period, quarterly basic EPS has ranged between a loss of US$0.22 and a loss of US$1.82, so the latest...
NYSE:MUR
NYSE:MUROil and Gas

Is Murphy Oil (MUR) Still Attractive After An 88% One Year Share Price Surge

If you are wondering whether Murphy Oil at around US$38.27 is offering value or just riding momentum, the recent share performance gives you plenty to think about. The stock has seen a 1 year return of 88.2% and is up 17.8% year to date, despite shorter term pullbacks with a 7 day return showing an 8.4% decline and a 30 day return showing a 10.5% decline. Recent coverage has focused on Murphy Oil as part of broader conversations around US oil and gas stocks, with attention on how producers...
NYSE:G
NYSE:GProfessional Services

Genpact (G) Maintains 10.9% Net Margin Challenging Bearish AI Cost Narratives

Genpact (G) has wrapped up FY 2025 with fourth quarter revenue of about US$1.3 billion and basic EPS of US$0.83, alongside trailing twelve month revenue of roughly US$5.1 billion and EPS of US$3.18, with earnings over the past year reported as growing 7.6%. Over recent periods the company has seen quarterly revenue move from US$1,248.7 million and EPS of US$0.81 in Q4 FY 2024 to US$1,319.3 million and EPS of US$0.83 in Q4 FY 2025. Trailing twelve month net income sits at US$552.5 million and...
NasdaqCM:OCGN
NasdaqCM:OCGNBiotechs

Ocugen (OCGN) Is Down 16.8% After Convertible Notes Deal Extends Cash Runway - What's Changed

In early May 2026, Ocugen reported first-quarter revenue of US$1.53 million alongside a net loss of US$19.18 million, while also closing a US$115 million private offering of 6.75% Convertible Senior Notes due 2034 and using about US$32.7 million to retire its Avenue loan. These updates both highlight Ocugen’s ongoing cash burn and materially improve its liquidity profile, with management indicating the new financing extends the company’s cash runway and supports continued advancement of its...
NasdaqGS:SLDE
NasdaqGS:SLDEInsurance

Slide Insurance Enters California As Valuation Gap And Growth Risks Stand Out

Slide Insurance Holdings (NasdaqGS:SLDE) has entered the California market with a new excess and surplus lines residential property insurance program. The company has written its first California policy, marking the start of its operations in one of the largest U.S. property insurance markets. For investors watching property insurers, California represents a complex and heavily scrutinized market, especially for residential coverage. By using an excess and surplus lines structure, Slide...
NasdaqGS:GLUE
NasdaqGS:GLUEBiotechs

A Look At Monte Rosa Therapeutics (GLUE) Valuation After Strong Recent Share Price Momentum

Recent performance snapshot Monte Rosa Therapeutics (GLUE) has drawn investor attention after recent share price moves, with the stock last closing at $19.81 and delivering a return of 15.7% over the past month. See our latest analysis for Monte Rosa Therapeutics. While the recent 15.7% one-month share price return has been strong, the 29.4% year-to-date share price return and very large one-year total shareholder return suggest that momentum has been building over a longer period. If you are...
NasdaqGS:UPWK
NasdaqGS:UPWKProfessional Services

Upwork (UPWK) Margin Compression To 14.7% Tests Bullish Undervaluation Narrative

Upwork (UPWK) has just wrapped FY 2025 with fourth quarter revenue of US$198.4 million and basic EPS of US$0.12, alongside net income of US$15.6 million. This rounds out a year where trailing twelve month revenue came in at US$787.8 million and EPS at US$0.87. Over recent quarters the company has seen revenue move from US$191.5 million in Q4 2024 to between US$192.7 million and US$201.7 million across FY 2025, while quarterly EPS has ranged from US$0.12 to US$0.28. This sets up a story that...
NYSE:NET
NYSE:NETIT

Cloudflare (NET) Q4 Loss Narrows Yet Ongoing TTM Losses Test Bullish Profitability Narrative

Cloudflare FY 2025 earnings snapshot Cloudflare (NET) has wrapped up FY 2025 with fourth quarter revenue of US$614.5 million and basic EPS of a US$0.03 loss, alongside a trailing twelve month revenue base of about US$2.2 billion and a net loss of US$102.3 million. Over recent periods the company has seen revenue move from US$430.1 million in Q3 2024 to US$614.5 million in Q4 2025, while quarterly basic EPS has ranged between a loss of US$0.15 and a loss of US$0.00, underscoring an ongoing...
NasdaqGS:CZR
NasdaqGS:CZRHospitality

Will Caesars’ Narrowed Loss and New Venues Reshape Caesars Entertainment's (CZR) Investment Narrative?

In the first quarter of 2026, Caesars Entertainment reported higher sales of US$2,153 million and revenue of US$2,870 million, while reducing its net loss to US$98 million compared with the prior year. Alongside these improved results, Caesars has been expanding its entertainment offerings with new venues such as OMNIA Dayclub & Skybar in Las Vegas and the upcoming Caesars Beach Club in Atlantic City, aiming to draw more visitors to its properties. Next, we will examine how Caesars’ narrowed...
NasdaqGS:ADBE
NasdaqGS:ADBESoftware

Is It Time To Reassess Adobe (ADBE) After Its Recent Share Price Slump?

If you are wondering whether Adobe's current share price really reflects what the stock could be worth, this breakdown will help you weigh up the numbers behind that question. Adobe closed at US$256.51, with returns of 4.2% over the last week and 6.8% over the last month, while the year-to-date return stands at a 23.0% decline and the 1-year return at a 33.2% decline. Recent moves in the stock sit alongside ongoing attention on Adobe's position in creative software and digital media, as...
NYSE:RKT
NYSE:RKTDiversified Financial

Rocket Companies (RKT) Swings To Q4 Profit And Tests Bullish Turnaround Narrative

Rocket Companies (RKT) closed FY 2025 with fourth quarter revenue of US$2.8b, basic EPS of US$0.02 and net income of US$68.0m, setting a clear marker for how the year wrapped up. Over recent periods the company has seen quarterly revenue move from US$1.9b in Q4 2024 to US$2.8b in Q4 2025, while basic EPS shifted from US$0.23 to US$0.02, and net income moved from US$33.5m to US$68.0m. This provides a clear view of how the top and bottom lines translated into current margins and overall...
NasdaqGM:INOD
NasdaqGM:INODProfessional Services

Innodata (INOD) Margin Compression Challenges Bullish AI Growth Narrative After FY 2025 Results

Innodata (INOD) just wrapped up FY 2025 with fourth quarter revenue of US$72.4 million and basic EPS of US$0.28, while trailing twelve month revenue came in at US$251.7 million and basic EPS at US$1.01. Over recent quarters the company has seen revenue move from US$59.2 million in Q4 2024 to US$72.4 million in Q4 2025, with basic EPS shifting from US$0.34 to US$0.28 over the same period. This sets up a picture where growth expectations and margin trends will be front of mind for investors...
NYSE:MRP
NYSE:MRPSpecialized REITs

Is It Time To Reassess Millrose Properties (MRP) After The Recent Share Price Pullback

If you are wondering whether Millrose Properties at around US$26.90 still offers value, the starting point is to understand what the current price implies about the business. The stock is up 14.1% over the last year, even though it has seen a 12.3% decline over the past week and a 3.0% decline over the past month, with a 9.8% decline year to date. This may have shifted how some investors think about its risk and reward trade off. Recent coverage has focused on Millrose Properties as a...
NasdaqGS:CCEC
NasdaqGS:CCECShipping

Capital Clean Energy Carriers TTM Margin Surge Challenges Bearish Narratives On Profit Durability

Capital Clean Energy Carriers (CCEC) has just wrapped up FY 2025 with fourth quarter revenue of US$86.8 million and basic EPS of US$0.46. Trailing 12 month EPS came in at US$1.92 as earnings over that period were very large compared with the prior year. The company has seen revenue on a trailing 12 month basis move from US$339.5 million in FY 2024 to US$392.7 million in FY 2025. Over the same period, EPS shifted from US$0.13 to US$1.92 and net profit margin moved from 2.2% to 28.9%. These...
NYSE:GNW
NYSE:GNWInsurance

How Genworth’s Buybacks, Enact and CareScout Build-Out At Genworth Financial (GNW) Has Changed Its Investment Story

Genworth Financial reported past first-quarter 2026 results with revenue of US$1,777 million and net income of US$47 million, alongside modestly lower earnings per share year over year. The company also completed a sizeable share repurchase program and highlighted Enact’s contribution and the build-out of CareScout as key parts of its longer-term plan. Next, we will examine how Genworth’s continued share repurchases shape the company’s investment narrative and its appeal to different...
NasdaqGS:XRAY
NasdaqGS:XRAYMedical Equipment

Is Dentsply Sirona (XRAY) Now Offering Value After A 28% One Year Share Price Slide

If you are wondering whether DENTSPLY SIRONA stock is starting to look interesting at current levels, its recent price and valuation signals give you a lot to think about. The share price sits at US$10.96 after a 6.7% decline over the last week, a 4.9% decline over the last month and a 28.5% decline over the last year, which may change how you view both its risk and potential reward. Recent coverage around DENTSPLY SIRONA has focused on its position within the medical equipment space and how...